MX2007007722A - Sales de amonio cuaternario como antagonistas de m3. - Google Patents
Sales de amonio cuaternario como antagonistas de m3.Info
- Publication number
- MX2007007722A MX2007007722A MX2007007722A MX2007007722A MX2007007722A MX 2007007722 A MX2007007722 A MX 2007007722A MX 2007007722 A MX2007007722 A MX 2007007722A MX 2007007722 A MX2007007722 A MX 2007007722A MX 2007007722 A MX2007007722 A MX 2007007722A
- Authority
- MX
- Mexico
- Prior art keywords
- methyl
- acetoxy
- hydroxy
- ethyl
- pipe
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title description 11
- 150000003242 quaternary ammonium salts Chemical class 0.000 title description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 133
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- -1 isoxazol-3-yl-carbamoyl-methyl Chemical group 0.000 claims description 334
- 125000004432 carbon atom Chemical group C* 0.000 claims description 153
- 125000000217 alkyl group Chemical group 0.000 claims description 67
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 60
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 52
- 125000002837 carbocyclic group Chemical group 0.000 claims description 52
- 125000000623 heterocyclic group Chemical group 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 49
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 43
- 229910052757 nitrogen Inorganic materials 0.000 claims description 40
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 38
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 38
- 239000001301 oxygen Chemical group 0.000 claims description 38
- 229910052760 oxygen Inorganic materials 0.000 claims description 38
- 239000011593 sulfur Chemical group 0.000 claims description 38
- 229910052717 sulfur Chemical group 0.000 claims description 38
- 125000005842 heteroatom Chemical group 0.000 claims description 37
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 35
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 33
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 31
- 229910052799 carbon Inorganic materials 0.000 claims description 29
- 238000002360 preparation method Methods 0.000 claims description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 125000002947 alkylene group Chemical group 0.000 claims description 13
- 150000001721 carbon Chemical group 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 9
- 230000000414 obstructive effect Effects 0.000 claims description 9
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 229940088679 drug related substance Drugs 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 125000004306 triazinyl group Chemical group 0.000 claims description 6
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims description 5
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 239000000739 antihistaminic agent Substances 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 208000023504 respiratory system disease Diseases 0.000 claims description 4
- 159000000000 sodium salts Chemical class 0.000 claims description 4
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 230000001387 anti-histamine Effects 0.000 claims description 3
- 229940124630 bronchodilator Drugs 0.000 claims description 3
- 239000000850 decongestant Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 229940127557 pharmaceutical product Drugs 0.000 claims description 3
- BSUGGQWXYRDVEF-HHHXNRCGSA-N C[C@@](CCOC(C1(C2=CC=CC=C2C2=C1C=CC=C2)O)=O)(C1=CC=CC=C1)N1CCCC1 Chemical compound C[C@@](CCOC(C1(C2=CC=CC=C2C2=C1C=CC=C2)O)=O)(C1=CC=CC=C1)N1CCCC1 BSUGGQWXYRDVEF-HHHXNRCGSA-N 0.000 claims description 2
- 102100022404 E3 ubiquitin-protein ligase Midline-1 Human genes 0.000 claims description 2
- 101710102210 E3 ubiquitin-protein ligase Midline-1 Proteins 0.000 claims description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 2
- FXPAIHFBPFLXOL-IEZXHERLSA-N [(1r)-1-methyl-1-(3-pyridin-3-ylpropyl)pyrrolidin-1-ium-2-yl]methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C([N@@+]1(C)C(CCC1)COC(=O)C(O)(C1CCCCC1)C=1C=CC=CC=1)CCC1=CC=CN=C1 FXPAIHFBPFLXOL-IEZXHERLSA-N 0.000 claims description 2
- IJDFJOPSIWYRJH-JGVIILGRSA-N [(1r)-1-methyl-1-(3-pyrimidin-2-ylpropyl)pyrrolidin-1-ium-2-yl]methyl 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C([N@+]1(C)C(CCC1)COC(=O)C(O)(C1CCCC1)C=1C=CC=CC=1)CCC1=NC=CC=N1 IJDFJOPSIWYRJH-JGVIILGRSA-N 0.000 claims description 2
- ZQYCATGTANJQRM-RMBIHJOLSA-N [(1r)-1-methyl-1-[2-(1,2-oxazol-3-yl)ethyl]pyrrolidin-1-ium-2-yl]methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C([N@+]1(C)C(CCC1)COC(=O)C(O)(C1CCCCC1)C=1C=CC=CC=1)CC=1C=CON=1 ZQYCATGTANJQRM-RMBIHJOLSA-N 0.000 claims description 2
- YHDKYTKDRGLISO-HNHZEOAVSA-N [(1r)-1-methyl-1-[2-(1,2-oxazol-3-yl)ethyl]pyrrolidin-1-ium-2-yl]methyl 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C([N@+]1(C)C(CCC1)COC(=O)C(O)(C1CCCC1)C=1C=CC=CC=1)CC=1C=CON=1 YHDKYTKDRGLISO-HNHZEOAVSA-N 0.000 claims description 2
- PCBBHWPBJQRTBO-VLEDXSGQSA-N [(1r)-1-methyl-1-[3-(1,2-oxazol-3-yl)propyl]piperidin-1-ium-3-yl] 9-hydroxyfluorene-9-carboxylate Chemical compound C([N@@+]1(C)CC(CCC1)OC(=O)C1(O)C2=CC=CC=C2C2=CC=CC=C21)CCC=1C=CON=1 PCBBHWPBJQRTBO-VLEDXSGQSA-N 0.000 claims description 2
- UYACEGMWLIYPRF-YDMIDMJISA-N [(1r)-1-methyl-1-[3-(1,2-oxazol-3-yl)propyl]pyrrolidin-1-ium-2-yl]methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C([N@+]1(C)C(CCC1)COC(=O)C(O)(C1CCCCC1)C=1C=CC=CC=1)CCC=1C=CON=1 UYACEGMWLIYPRF-YDMIDMJISA-N 0.000 claims description 2
- YWQSNZTXJJIDLN-AVJYQCBHSA-N [(3R)-3-phenyl-3-pyrrolidin-1-ylbutyl] 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C[C@@](CCOC(=O)C(C1CCCC1)(C2=CC=CC=C2)O)(C3=CC=CC=C3)N4CCCC4 YWQSNZTXJJIDLN-AVJYQCBHSA-N 0.000 claims description 2
- SWJOGWPHIUNYQU-UHFFFAOYSA-N [1-methyl-1-(2-pyridin-4-ylethyl)piperidin-1-ium-4-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1CC(OC(=O)C(O)(C2CCCC2)C=2C=CC=CC=2)CC[N+]1(C)CCC1=CC=NC=C1 SWJOGWPHIUNYQU-UHFFFAOYSA-N 0.000 claims description 2
- PBCDNIHWFCTVKP-UHFFFAOYSA-N [1-methyl-1-(2-pyrimidin-5-ylethyl)piperidin-1-ium-4-yl] 2-hydroxy-2,2-diphenylacetate Chemical compound C1CC(OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC[N+]1(C)CCC1=CN=CN=C1 PBCDNIHWFCTVKP-UHFFFAOYSA-N 0.000 claims description 2
- GMJNEKBDFXGXHV-UHFFFAOYSA-N [1-methyl-1-(3-pyrazin-2-ylpropyl)piperidin-1-ium-4-yl] 2-hydroxy-2,2-diphenylacetate Chemical compound C1CC(OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC[N+]1(C)CCCC1=CN=CC=N1 GMJNEKBDFXGXHV-UHFFFAOYSA-N 0.000 claims description 2
- QUZLYWNRLNLDCC-UHFFFAOYSA-N [1-methyl-1-(3-pyrimidin-2-ylpropyl)piperidin-1-ium-4-yl] 2-hydroxy-2,2-diphenylacetate Chemical compound C1CC(OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC[N+]1(C)CCCC1=NC=CC=N1 QUZLYWNRLNLDCC-UHFFFAOYSA-N 0.000 claims description 2
- RHHFFYAUQYIAOM-UHFFFAOYSA-N [1-methyl-1-(3-pyrimidin-4-ylpropyl)piperidin-1-ium-4-yl] 2-hydroxy-2,2-diphenylacetate Chemical compound C1CC(OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC[N+]1(C)CCCC1=CC=NC=N1 RHHFFYAUQYIAOM-UHFFFAOYSA-N 0.000 claims description 2
- NTCHQOXFRQYAMT-UHFFFAOYSA-N [1-methyl-1-[2-(1,2-oxazol-3-yl)ethyl]piperidin-1-ium-4-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C1CC(OC(=O)C(O)(C2CCCCC2)C=2C=CC=CC=2)CC[N+]1(C)CCC=1C=CON=1 NTCHQOXFRQYAMT-UHFFFAOYSA-N 0.000 claims description 2
- SBMLBVDGMBNGLQ-UHFFFAOYSA-N [1-methyl-1-[3-(1,2-oxazol-3-yl)propyl]piperidin-1-ium-4-yl] 2-hydroxy-2,2-diphenylacetate Chemical compound C1CC(OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC[N+]1(C)CCCC=1C=CON=1 SBMLBVDGMBNGLQ-UHFFFAOYSA-N 0.000 claims description 2
- IWVYENAUFSXCPZ-UHFFFAOYSA-N [1-methyl-1-[3-(1,2-oxazol-3-yl)propyl]piperidin-1-ium-4-yl] 9-hydroxyfluorene-9-carboxylate Chemical compound C1CC(OC(=O)C2(O)C3=CC=CC=C3C3=CC=CC=C32)CC[N+]1(C)CCCC=1C=CON=1 IWVYENAUFSXCPZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 125000002346 iodo group Chemical group I* 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- PXJMEKXBONLMNG-UHFFFAOYSA-N 1-(2-pyridin-4-ylethyl)piperazine Chemical compound C1CNCCN1CCC1=CC=NC=C1 PXJMEKXBONLMNG-UHFFFAOYSA-N 0.000 claims 1
- 206010027654 Allergic conditions Diseases 0.000 claims 1
- GWNKRNKKALHHNH-OAQYLSRUSA-N CC(C)(C1=CC=CC=C1)N(CCC1)C[C@@H]1OC(C1(C2=CC=CC=C2C2=C1C=CC=C2)O)=O Chemical compound CC(C)(C1=CC=CC=C1)N(CCC1)C[C@@H]1OC(C1(C2=CC=CC=C2C2=C1C=CC=C2)O)=O GWNKRNKKALHHNH-OAQYLSRUSA-N 0.000 claims 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-O Piperidinium(1+) Chemical compound C1CC[NH2+]CC1 NQRYJNQNLNOLGT-UHFFFAOYSA-O 0.000 claims 1
- ACSNSSZUTWIPAK-NLLRYDLESA-N [(1r)-1-methyl-1-(2-pyridin-4-ylethyl)pyrrolidin-1-ium-2-yl]methyl 9-hydroxyfluorene-9-carboxylate Chemical compound C([N@+]1(C)C(CCC1)COC(=O)C1(O)C2=CC=CC=C2C2=CC=CC=C21)CC1=CC=NC=C1 ACSNSSZUTWIPAK-NLLRYDLESA-N 0.000 claims 1
- UEUNOSAUIJHPNY-LXNFMVHRSA-N [(1r)-1-methyl-1-(2-pyrimidin-4-ylethyl)pyrrolidin-1-ium-2-yl]methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C([N@+]1(C)C(CCC1)COC(=O)C(O)(C1CCCCC1)C=1C=CC=CC=1)CC1=CC=NC=N1 UEUNOSAUIJHPNY-LXNFMVHRSA-N 0.000 claims 1
- JHFFEXICUTYWMA-DMIDXSHCSA-O [(1r)-1-methyl-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]pyrrolidin-1-ium-2-yl]methyl 9-hydroxyfluorene-9-carboxylate Chemical compound O1C(C)=CC(NC(=O)C[N@+]2(C)C(CCC2)COC(=O)C2(O)C3=CC=CC=C3C3=CC=CC=C32)=N1 JHFFEXICUTYWMA-DMIDXSHCSA-O 0.000 claims 1
- LIKPAYYBEMLTAF-ZOGOTRPCSA-N [(1r)-1-methyl-1-[3-(1,2-oxazol-3-yl)propyl]pyrrolidin-1-ium-2-yl]methyl 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C([N@+]1(C)C(CCC1)COC(=O)C(O)(C1CCCC1)C=1C=CC=CC=1)CCC=1C=CON=1 LIKPAYYBEMLTAF-ZOGOTRPCSA-N 0.000 claims 1
- OWGXFJYQRMSCHI-VXAWTHLYSA-M [1-methyl-1-(2-phenoxyethyl)piperidin-1-ium-4-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C1CC(OC(=O)[C@@](O)(C2CCCC2)C=2C=CC=CC=2)CC[N+]1(C)CCOC1=CC=CC=C1 OWGXFJYQRMSCHI-VXAWTHLYSA-M 0.000 claims 1
- IWWKILADIPQPFZ-UHFFFAOYSA-N [1-methyl-1-(2-pyrimidin-5-ylethyl)piperidin-1-ium-4-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1CC(OC(=O)C(O)(C2CCCC2)C=2C=CC=CC=2)CC[N+]1(C)CCC1=CN=CN=C1 IWWKILADIPQPFZ-UHFFFAOYSA-N 0.000 claims 1
- QETMOMDJQZZOCA-NOWWTIMUSA-M [1-methyl-1-(3-phenylpropyl)piperidin-1-ium-4-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C1CC(OC(=O)[C@@](O)(C2CCCC2)C=2C=CC=CC=2)CC[N+]1(C)CCCC1=CC=CC=C1 QETMOMDJQZZOCA-NOWWTIMUSA-M 0.000 claims 1
- KOHJAYRHXHVRRC-UHFFFAOYSA-N [1-methyl-1-(3-phenylpropyl)piperidin-1-ium-4-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1CC(OC(=O)C(O)(C2CCCC2)C=2C=CC=CC=2)CC[N+]1(C)CCCC1=CC=CC=C1 KOHJAYRHXHVRRC-UHFFFAOYSA-N 0.000 claims 1
- OMVDTNMUPRQIRK-UHFFFAOYSA-N [1-methyl-1-(3-phenylpropyl)piperidin-1-ium-4-yl] 9-hydroxyfluorene-9-carboxylate Chemical compound C1CC(OC(=O)C2(O)C3=CC=CC=C3C3=CC=CC=C32)CC[N+]1(C)CCCC1=CC=CC=C1 OMVDTNMUPRQIRK-UHFFFAOYSA-N 0.000 claims 1
- OARGCDXTKMTSDP-UHFFFAOYSA-N [1-methyl-1-(3-pyridin-2-ylpropyl)piperidin-1-ium-4-yl] 2-hydroxy-2,2-diphenylacetate Chemical compound C1CC(OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC[N+]1(C)CCCC1=CC=CC=N1 OARGCDXTKMTSDP-UHFFFAOYSA-N 0.000 claims 1
- GUIZRXDRZOZFIF-UHFFFAOYSA-N [1-methyl-1-(3-pyridin-4-ylpropyl)piperidin-1-ium-4-yl] 2-hydroxy-2,2-diphenylacetate Chemical compound C1CC(OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC[N+]1(C)CCCC1=CC=NC=C1 GUIZRXDRZOZFIF-UHFFFAOYSA-N 0.000 claims 1
- KISRQZZOSBQVBH-UHFFFAOYSA-N [1-methyl-1-(3-pyrimidin-5-ylpropyl)piperidin-1-ium-4-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1CC(OC(=O)C(O)(C2CCCC2)C=2C=CC=CC=2)CC[N+]1(C)CCCC1=CN=CN=C1 KISRQZZOSBQVBH-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 102000007202 Muscarinic M3 Receptor Human genes 0.000 abstract 1
- 108010008405 Muscarinic M3 Receptor Proteins 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 description 37
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- 239000000203 mixture Substances 0.000 description 33
- 239000003795 chemical substances by application Substances 0.000 description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 16
- 208000006673 asthma Diseases 0.000 description 15
- 239000002253 acid Substances 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- YTRNSQPXEDGWMR-UHFFFAOYSA-N alpha-Cyclohexylmandelic acid Chemical compound C=1C=CC=CC=1C(O)(C(=O)O)C1CCCCC1 YTRNSQPXEDGWMR-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 125000004076 pyridyl group Chemical group 0.000 description 10
- 125000001544 thienyl group Chemical group 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- GIWMPTVSSKUNBX-UHFFFAOYSA-N 2-bromo-n-(1,2-oxazol-3-yl)acetamide Chemical compound BrCC(=O)NC=1C=CON=1 GIWMPTVSSKUNBX-UHFFFAOYSA-N 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 7
- 150000002367 halogens Chemical class 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 239000012453 solvate Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- UKANCZCEGQDKGF-ZCFIWIBFSA-N (3r)-1-methylpiperidin-3-ol Chemical compound CN1CCC[C@@H](O)C1 UKANCZCEGQDKGF-ZCFIWIBFSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 6
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000002541 furyl group Chemical group 0.000 description 6
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 6
- 238000004949 mass spectrometry Methods 0.000 description 6
- 125000002971 oxazolyl group Chemical group 0.000 description 6
- 125000003386 piperidinyl group Chemical group 0.000 description 6
- 125000000168 pyrrolyl group Chemical group 0.000 description 6
- 210000002345 respiratory system Anatomy 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 125000001113 thiadiazolyl group Chemical group 0.000 description 6
- 125000001425 triazolyl group Chemical group 0.000 description 6
- WFLUEQCOAQCQLP-UHFFFAOYSA-N 2-cyclopentyl-2-hydroxy-2-phenylacetic acid Chemical compound C=1C=CC=CC=1C(O)(C(=O)O)C1CCCC1 WFLUEQCOAQCQLP-UHFFFAOYSA-N 0.000 description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 5
- LZCOQTDXKCNBEE-XJMZPCNVSA-N N-methylscopolamine Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 LZCOQTDXKCNBEE-XJMZPCNVSA-N 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- BAUWRHPMUVYFOD-UHFFFAOYSA-N 1-methylpiperidin-4-ol Chemical compound CN1CCC(O)CC1 BAUWRHPMUVYFOD-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 description 4
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000001624 naphthyl group Chemical group 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 125000002098 pyridazinyl group Chemical group 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- RHFWLPWDOYJEAL-UHFFFAOYSA-N 1,2-oxazol-3-amine Chemical compound NC=1C=CON=1 RHFWLPWDOYJEAL-UHFFFAOYSA-N 0.000 description 3
- WEKZGHGDYVFQBW-UHFFFAOYSA-M 1-methyl-1-(3-phenylpropyl)piperidin-1-ium-4-ol;bromide Chemical compound [Br-].C=1C=CC=CC=1CCC[N+]1(C)CCC(O)CC1 WEKZGHGDYVFQBW-UHFFFAOYSA-M 0.000 description 3
- IJUQDFPFXVMQGG-UHFFFAOYSA-N 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetic acid Chemical compound C=1C=CSC=1C(O)(C(=O)O)C1CCCCC1 IJUQDFPFXVMQGG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
- 206010006482 Bronchospasm Diseases 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- VCOJPHPOVDIRJK-ZCFIWIBFSA-N [(2r)-1-methylpyrrolidin-2-yl]methanol Chemical compound CN1CCC[C@@H]1CO VCOJPHPOVDIRJK-ZCFIWIBFSA-N 0.000 description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
- 125000006193 alkinyl group Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- UKXSKSHDVLQNKG-UHFFFAOYSA-N benzilic acid Chemical compound C=1C=CC=CC=1C(O)(C(=O)O)C1=CC=CC=C1 UKXSKSHDVLQNKG-UHFFFAOYSA-N 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 230000007885 bronchoconstriction Effects 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 3
- 125000001786 isothiazolyl group Chemical group 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- DCYGAPKNVCQNOE-UHFFFAOYSA-N 2,2,2-triphenylacetic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)O)C1=CC=CC=C1 DCYGAPKNVCQNOE-UHFFFAOYSA-N 0.000 description 2
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
- WKCWELSTTLPNKW-UHFFFAOYSA-N 2-bromo-n-pyrazin-2-ylacetamide Chemical compound BrCC(=O)NC1=CN=CC=N1 WKCWELSTTLPNKW-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000017925 CHRM3 Human genes 0.000 description 2
- 101150060249 CHRM3 gene Proteins 0.000 description 2
- 101150015280 Cel gene Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010013647 Drowning Diseases 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- GXAMYUGOODKVRM-UHFFFAOYSA-N Flurecol Chemical compound C1=CC=C2C(C(=O)O)(O)C3=CC=CC=C3C2=C1 GXAMYUGOODKVRM-UHFFFAOYSA-N 0.000 description 2
- 206010020853 Hypertonic bladder Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- VCEDNUBOZUHUHB-NPRFROTHSA-N [(1r)-1-methyl-1-(3-pyridin-3-ylpropyl)pyrrolidin-1-ium-2-yl]methyl 2-hydroxy-2,2-diphenylacetate Chemical compound C([N@@+]1(C)C(CCC1)COC(=O)C(O)(C=1C=CC=CC=1)C=1C=CC=CC=1)CCC1=CC=CN=C1 VCEDNUBOZUHUHB-NPRFROTHSA-N 0.000 description 2
- JEFPYBSKSPXZQI-CICLSPSMSA-N [(1r)-1-methyl-1-(3-pyridin-4-ylpropyl)pyrrolidin-1-ium-2-yl]methyl 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C([N@@+]1(C)C(CCC1)COC(=O)C(O)(C1CCCC1)C=1C=CC=CC=1)CCC1=CC=NC=C1 JEFPYBSKSPXZQI-CICLSPSMSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000036428 airway hyperreactivity Effects 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000001022 anti-muscarinic effect Effects 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 229940047583 cetamide Drugs 0.000 description 2
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 229940038891 d-phen Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 2
- 206010035653 pneumoconiosis Diseases 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- SZYCXFJWSGHCLZ-SSDOTTSWSA-N (2R)-2-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-1-carboxylic acid Chemical compound CC(C)(C)OC(=O)[C@H]1CCCN1C(O)=O SZYCXFJWSGHCLZ-SSDOTTSWSA-N 0.000 description 1
- UTUPESZTMCQTJC-RXMQYKEDSA-N (3r)-3-hydroxypiperidine-1-carboxylic acid Chemical compound O[C@@H]1CCCN(C(O)=O)C1 UTUPESZTMCQTJC-RXMQYKEDSA-N 0.000 description 1
- VLECDMDGMKPUSK-NUBCRITNSA-N (3r)-piperidin-3-ol;hydrochloride Chemical compound Cl.O[C@@H]1CCCNC1 VLECDMDGMKPUSK-NUBCRITNSA-N 0.000 description 1
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- PMGQWSIVQFOFOQ-BDUVBVHRSA-N (e)-but-2-enedioic acid;(2r)-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.CN1CCC[C@@H]1CCOC(C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PMGQWSIVQFOFOQ-BDUVBVHRSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- KCZIUKYAJJEIQG-UHFFFAOYSA-N 1,3,5-triazin-2-amine Chemical compound NC1=NC=NC=N1 KCZIUKYAJJEIQG-UHFFFAOYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- KMWIRWYCRQWMOF-UHFFFAOYSA-M 1-methyl-1-(2-phenoxyethyl)piperidin-1-ium-4-ol;bromide Chemical compound [Br-].C=1C=CC=CC=1OCC[N+]1(C)CCC(O)CC1 KMWIRWYCRQWMOF-UHFFFAOYSA-M 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- PYHXGXCGESYPCW-UHFFFAOYSA-M 2,2-diphenylacetate Chemical compound C=1C=CC=CC=1C(C(=O)[O-])C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-M 0.000 description 1
- RRKRAAFZEQHDKI-UHFFFAOYSA-N 2-(1,2-oxazol-3-yl)acetamide Chemical compound NC(=O)CC=1C=CON=1 RRKRAAFZEQHDKI-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- YVZJLODNEHZRNP-UHFFFAOYSA-N 2-bromo-n-(1,3,5-triazin-2-yl)acetamide Chemical compound BrCC(=O)NC1=NC=NC=N1 YVZJLODNEHZRNP-UHFFFAOYSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- JJFOBACUIRKUPN-UHFFFAOYSA-N 2-bromoethoxybenzene Chemical compound BrCCOC1=CC=CC=C1 JJFOBACUIRKUPN-UHFFFAOYSA-N 0.000 description 1
- WBJWXIQDBDZMAW-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carbonyl chloride Chemical compound C1=CC=CC2=C(C(Cl)=O)C(O)=CC=C21 WBJWXIQDBDZMAW-UHFFFAOYSA-N 0.000 description 1
- GIWRVUADKUVEGU-UHFFFAOYSA-N 2-oxo-2-thiophen-2-ylacetic acid Chemical compound OC(=O)C(=O)C1=CC=CS1 GIWRVUADKUVEGU-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- DDYUBCCTNHWSQM-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)propanamide Chemical compound COC1=CC=C(C(CC(N)=O)N2C(C3=CC=CC=C3C2=O)=O)C=C1OC1CCCC1 DDYUBCCTNHWSQM-UHFFFAOYSA-N 0.000 description 1
- HLBOAQSKBNNHMW-UHFFFAOYSA-N 3-(3-methoxyphenyl)pyridine Chemical compound COC1=CC=CC(C=2C=NC=CC=2)=C1 HLBOAQSKBNNHMW-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- XMZQWZJMTBCUFT-UHFFFAOYSA-N 3-bromopropylbenzene Chemical compound BrCCCC1=CC=CC=C1 XMZQWZJMTBCUFT-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-M 4-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-M 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- IHOXNOQMRZISPV-YJYMSZOUSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]azaniumyl]ethyl]-2-oxo-1h-quinolin-8-olate Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 IHOXNOQMRZISPV-YJYMSZOUSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000033116 Asbestos intoxication Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 208000007596 Byssinosis Diseases 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- GGUSXUULJRTFLQ-UHFFFAOYSA-N CC(C)(C1=CC=CC=C1)N(CC1)CCC1OC(C1(C2=CC=CC=C2C2=C1C=CC=C2)O)=O Chemical compound CC(C)(C1=CC=CC=C1)N(CC1)CCC1OC(C1(C2=CC=CC=C2C2=C1C=CC=C2)O)=O GGUSXUULJRTFLQ-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 229940122444 Chemokine receptor antagonist Drugs 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010063057 Cystitis noninfective Diseases 0.000 description 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 1
- 229930182820 D-proline Natural products 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- RRJFVPUCXDGFJB-UHFFFAOYSA-N Fexofenadine hydrochloride Chemical compound Cl.C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RRJFVPUCXDGFJB-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 238000000023 Kugelrohr distillation Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
- 206010029279 Neurogenic bladder Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000027771 Obstructive airways disease Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-O Pyrrolidinium ion Chemical compound C1CC[NH2+]C1 RWRDLPDLKQPQOW-UHFFFAOYSA-O 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- RUOGJYKOQBFJIG-UHFFFAOYSA-N SCH-351591 Chemical compound C12=CC=C(C(F)(F)F)N=C2C(OC)=CC=C1C(=O)NC1=C(Cl)C=[N+]([O-])C=C1Cl RUOGJYKOQBFJIG-UHFFFAOYSA-N 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010052568 Urticaria chronic Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- RBDIINYARJHDCN-KFNCMCARSA-O [(1r)-1-(2-amino-2-oxo-1-pyridazin-3-ylethyl)-1-methylpyrrolidin-1-ium-2-yl]methyl 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C([N@@+]1(C)C(C(N)=O)C=2N=NC=CC=2)CCC1COC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 RBDIINYARJHDCN-KFNCMCARSA-O 0.000 description 1
- MKBHWFNYVBQOOT-UKKNISFUSA-O [(1r)-1-[2-amino-2-oxo-1-(1,3,5-triazin-2-yl)ethyl]-1-methylpyrrolidin-1-ium-2-yl]methyl 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C([N@@+]1(C)C(C(N)=O)C=2N=CN=CN=2)CCC1COC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 MKBHWFNYVBQOOT-UKKNISFUSA-O 0.000 description 1
- LWBOOSQCFZTRNO-NORZDRCHSA-N [(1r)-1-methyl-1-(2-pyrazin-2-ylethyl)piperidin-1-ium-3-yl] 9-hydroxyfluorene-9-carboxylate Chemical compound C([N@+]1(C)CC(CCC1)OC(=O)C1(O)C2=CC=CC=C2C2=CC=CC=C21)CC1=CN=CC=N1 LWBOOSQCFZTRNO-NORZDRCHSA-N 0.000 description 1
- WWJPZEULIBUCGD-HOINCLMKSA-N [(1r)-1-methyl-1-(2-pyrazin-2-ylethyl)pyrrolidin-1-ium-2-yl]methyl 2-hydroxy-2,2-diphenylacetate Chemical compound C([N@+]1(C)C(CCC1)COC(=O)C(O)(C=1C=CC=CC=1)C=1C=CC=CC=1)CC1=CN=CC=N1 WWJPZEULIBUCGD-HOINCLMKSA-N 0.000 description 1
- JFHCWPCWIFCQND-CICLSPSMSA-N [(1r)-1-methyl-1-(2-pyridin-2-ylethyl)piperidin-1-ium-3-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C([N@+]1(C)CC(CCC1)OC(=O)C(O)(C1CCCCC1)C=1C=CC=CC=1)CC1=CC=CC=N1 JFHCWPCWIFCQND-CICLSPSMSA-N 0.000 description 1
- CODOGHHZBCHREB-SKGNGKIFSA-N [(1r)-1-methyl-1-(2-pyridin-2-ylethyl)pyrrolidin-1-ium-2-yl]methyl 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C([N@+]1(C)C(CCC1)COC(=O)C(O)(C1CCCC1)C=1C=CC=CC=1)CC1=CC=CC=N1 CODOGHHZBCHREB-SKGNGKIFSA-N 0.000 description 1
- RQKJZPFVRFKLEM-NLLRYDLESA-N [(1r)-1-methyl-1-(2-pyridin-3-ylethyl)piperidin-1-ium-3-yl] 9-hydroxyfluorene-9-carboxylate Chemical compound C([N@+]1(C)CC(CCC1)OC(=O)C1(O)C2=CC=CC=C2C2=CC=CC=C21)CC1=CC=CN=C1 RQKJZPFVRFKLEM-NLLRYDLESA-N 0.000 description 1
- NKQOOYOLZDBLOK-CICLSPSMSA-N [(1r)-1-methyl-1-(2-pyridin-3-ylethyl)pyrrolidin-1-ium-2-yl]methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C([N@+]1(C)C(CCC1)COC(=O)C(O)(C1CCCCC1)C=1C=CC=CC=1)CC1=CC=CN=C1 NKQOOYOLZDBLOK-CICLSPSMSA-N 0.000 description 1
- PABSRICYZVAOKH-SNSSHHSLSA-N [(1r)-1-methyl-1-(2-pyridin-3-ylethyl)pyrrolidin-1-ium-2-yl]methyl 2-hydroxy-2,2-diphenylacetate Chemical compound C([N@+]1(C)C(CCC1)COC(=O)C(O)(C=1C=CC=CC=1)C=1C=CC=CC=1)CC1=CC=CN=C1 PABSRICYZVAOKH-SNSSHHSLSA-N 0.000 description 1
- SXMJOAFFLWQYEW-SNSSHHSLSA-N [(1r)-1-methyl-1-(2-pyridin-4-ylethyl)piperidin-1-ium-3-yl] 2-hydroxy-2,2-diphenylacetate Chemical compound C([N@+]1(C)CC(CCC1)OC(=O)C(O)(C=1C=CC=CC=1)C=1C=CC=CC=1)CC1=CC=NC=C1 SXMJOAFFLWQYEW-SNSSHHSLSA-N 0.000 description 1
- QJJSUKFZNKCQQC-SKGNGKIFSA-N [(1r)-1-methyl-1-(2-pyridin-4-ylethyl)pyrrolidin-1-ium-2-yl]methyl 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C([N@+]1(C)C(CCC1)COC(=O)C(O)(C1CCCC1)C=1C=CC=CC=1)CC1=CC=NC=C1 QJJSUKFZNKCQQC-SKGNGKIFSA-N 0.000 description 1
- WQPBOOJUTCSYJN-MGYSCDMNSA-N [(1r)-1-methyl-1-(2-pyrimidin-2-ylethyl)pyrrolidin-1-ium-2-yl]methyl 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C([N@+]1(C)C(CCC1)COC(=O)C(O)(C1CCCC1)C=1C=CC=CC=1)CC1=NC=CC=N1 WQPBOOJUTCSYJN-MGYSCDMNSA-N 0.000 description 1
- TZNKZAQKADUQED-HMFNHSOVSA-N [(1r)-1-methyl-1-(2-pyrimidin-4-ylethyl)piperidin-1-ium-3-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C([N@+]1(C)CC(CCC1)OC(=O)C(O)(C1CCCC1)C=1C=CC=CC=1)CC1=CC=NC=N1 TZNKZAQKADUQED-HMFNHSOVSA-N 0.000 description 1
- OMJWFFORNKEPIC-LXNFMVHRSA-N [(1r)-1-methyl-1-(2-pyrimidin-5-ylethyl)pyrrolidin-1-ium-2-yl]methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C([N@+]1(C)C(CCC1)COC(=O)C(O)(C1CCCCC1)C=1C=CC=CC=1)CC1=CN=CN=C1 OMJWFFORNKEPIC-LXNFMVHRSA-N 0.000 description 1
- FCWVPAWCVJIZOK-HMFNHSOVSA-N [(1r)-1-methyl-1-(2-pyrimidin-5-ylethyl)pyrrolidin-1-ium-2-yl]methyl 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C([N@+]1(C)C(CCC1)COC(=O)C(O)(C1CCCC1)C=1C=CC=CC=1)CC1=CN=CN=C1 FCWVPAWCVJIZOK-HMFNHSOVSA-N 0.000 description 1
- GRADLQDCSQHGNA-JSTCWRMYSA-N [(1r)-1-methyl-1-(3-phenylpropyl)piperidin-1-ium-3-yl] 9-hydroxyfluorene-9-carboxylate Chemical compound C([N@@+]1(C)CC(CCC1)OC(=O)C1(O)C2=CC=CC=C2C2=CC=CC=C21)CCC1=CC=CC=C1 GRADLQDCSQHGNA-JSTCWRMYSA-N 0.000 description 1
- AYBDPPICMUDFLI-ACZHUXRJSA-N [(1r)-1-methyl-1-(3-phenylpropyl)pyrrolidin-1-ium-2-yl]methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C([N@@+]1(C)C(CCC1)COC(=O)C(O)(C1CCCCC1)C=1C=CC=CC=1)CCC1=CC=CC=C1 AYBDPPICMUDFLI-ACZHUXRJSA-N 0.000 description 1
- JJAJRVDRKQIIPC-UYTNTSMZSA-N [(1r)-1-methyl-1-(3-phenylpropyl)pyrrolidin-1-ium-2-yl]methyl 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C([N@@+]1(C)C(CCC1)COC(=O)C(O)(C1CCCC1)C=1C=CC=CC=1)CCC1=CC=CC=C1 JJAJRVDRKQIIPC-UYTNTSMZSA-N 0.000 description 1
- MGLSMGVAEJHWGA-CICLSPSMSA-N [(1r)-1-methyl-1-(3-pyridin-2-ylpropyl)piperidin-1-ium-3-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C([N@@+]1(C)CC(CCC1)OC(=O)C(O)(C1CCCC1)C=1C=CC=CC=1)CCC1=CC=CC=N1 MGLSMGVAEJHWGA-CICLSPSMSA-N 0.000 description 1
- FWGOUZCZTLRRFC-NPRFROTHSA-N [(1r)-1-methyl-1-(3-pyridin-2-ylpropyl)piperidin-1-ium-3-yl] 2-hydroxy-2,2-diphenylacetate Chemical compound C([N@@+]1(C)CC(CCC1)OC(=O)C(O)(C=1C=CC=CC=1)C=1C=CC=CC=1)CCC1=CC=CC=N1 FWGOUZCZTLRRFC-NPRFROTHSA-N 0.000 description 1
- BJQGEMBFRDEYGV-NPRFROTHSA-N [(1r)-1-methyl-1-(3-pyridin-3-ylpropyl)piperidin-1-ium-3-yl] 2-hydroxy-2,2-diphenylacetate Chemical compound C([N@@+]1(C)CC(CCC1)OC(=O)C(O)(C=1C=CC=CC=1)C=1C=CC=CC=1)CCC1=CC=CN=C1 BJQGEMBFRDEYGV-NPRFROTHSA-N 0.000 description 1
- FGHVDCVFLFZAHB-CICLSPSMSA-N [(1r)-1-methyl-1-(3-pyridin-3-ylpropyl)pyrrolidin-1-ium-2-yl]methyl 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C([N@@+]1(C)C(CCC1)COC(=O)C(O)(C1CCCC1)C=1C=CC=CC=1)CCC1=CC=CN=C1 FGHVDCVFLFZAHB-CICLSPSMSA-N 0.000 description 1
- DNQXSYFJLWKWPL-IEZXHERLSA-N [(1r)-1-methyl-1-(3-pyridin-4-ylpropyl)piperidin-1-ium-3-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C([N@@+]1(C)CC(CCC1)OC(=O)C(O)(C1CCCCC1)C=1C=CC=CC=1)CCC1=CC=NC=C1 DNQXSYFJLWKWPL-IEZXHERLSA-N 0.000 description 1
- DRWOVYCTLQXXEG-NPRFROTHSA-N [(1r)-1-methyl-1-(3-pyridin-4-ylpropyl)piperidin-1-ium-3-yl] 2-hydroxy-2,2-diphenylacetate Chemical compound C([N@@+]1(C)CC(CCC1)OC(=O)C(O)(C=1C=CC=CC=1)C=1C=CC=CC=1)CCC1=CC=NC=C1 DRWOVYCTLQXXEG-NPRFROTHSA-N 0.000 description 1
- HSEQSGYNAIXGBJ-GEFZVGADSA-N [(1r)-1-methyl-1-(3-pyridin-4-ylpropyl)piperidin-1-ium-3-yl] 9-hydroxyfluorene-9-carboxylate Chemical compound C([N@@+]1(C)CC(CCC1)OC(=O)C1(O)C2=CC=CC=C2C2=CC=CC=C21)CCC1=CC=NC=C1 HSEQSGYNAIXGBJ-GEFZVGADSA-N 0.000 description 1
- UZTBMDJSBHNFOQ-NPRFROTHSA-N [(1r)-1-methyl-1-(3-pyridin-4-ylpropyl)pyrrolidin-1-ium-2-yl]methyl 2-hydroxy-2,2-diphenylacetate Chemical compound C([N@@+]1(C)C(CCC1)COC(=O)C(O)(C=1C=CC=CC=1)C=1C=CC=CC=1)CCC1=CC=NC=C1 UZTBMDJSBHNFOQ-NPRFROTHSA-N 0.000 description 1
- RZEJGXHXGWWHGE-LMXSBEAKSA-N [(1r)-1-methyl-1-(3-pyrimidin-2-ylpropyl)piperidin-1-ium-3-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C([N@@+]1(C)CC(CCC1)OC(=O)C(O)(C1CCCCC1)C=1C=CC=CC=1)CCC1=NC=CC=N1 RZEJGXHXGWWHGE-LMXSBEAKSA-N 0.000 description 1
- BMAXXTZHPUGPMA-FZNWDQQTSA-N [(1r)-1-methyl-1-(3-pyrimidin-2-ylpropyl)piperidin-1-ium-3-yl] 2-hydroxy-2,2-diphenylacetate Chemical compound C([N@@+]1(C)CC(CCC1)OC(=O)C(O)(C=1C=CC=CC=1)C=1C=CC=CC=1)CCC1=NC=CC=N1 BMAXXTZHPUGPMA-FZNWDQQTSA-N 0.000 description 1
- MAYIQFOJLMSUQA-ROBZXWEHSA-N [(1r)-1-methyl-1-(3-pyrimidin-2-ylpropyl)pyrrolidin-1-ium-2-yl]methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C([N@+]1(C)C(CCC1)COC(=O)C(O)(C1CCCCC1)C=1C=CC=CC=1)CCC1=NC=CC=N1 MAYIQFOJLMSUQA-ROBZXWEHSA-N 0.000 description 1
- IEVRNERHEBUKGH-AEXFLSAISA-N [(1r)-1-methyl-1-(3-pyrimidin-4-ylpropyl)piperidin-1-ium-3-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C([N@@+]1(C)CC(CCC1)OC(=O)C(O)(C1CCCCC1)C=1C=CC=CC=1)CCC1=CC=NC=N1 IEVRNERHEBUKGH-AEXFLSAISA-N 0.000 description 1
- PJZPGZKDQURXPE-PLAQUJHSSA-N [(1r)-1-methyl-1-(3-pyrimidin-4-ylpropyl)pyrrolidin-1-ium-2-yl]methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C([N@+]1(C)C(CCC1)COC(=O)C(O)(C1CCCCC1)C=1C=CC=CC=1)CCC1=CC=NC=N1 PJZPGZKDQURXPE-PLAQUJHSSA-N 0.000 description 1
- JJPNPSNSTGQFQF-AEXFLSAISA-N [(1r)-1-methyl-1-(3-pyrimidin-5-ylpropyl)piperidin-1-ium-3-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C([N@@+]1(C)CC(CCC1)OC(=O)C(O)(C1CCCCC1)C=1C=CC=CC=1)CCC1=CN=CN=C1 JJPNPSNSTGQFQF-AEXFLSAISA-N 0.000 description 1
- JTVRMZQFJLJITC-AEXFLSAISA-N [(1r)-1-methyl-1-(3-pyrimidin-5-ylpropyl)pyrrolidin-1-ium-2-yl]methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C([N@@+]1(C)C(CCC1)COC(=O)C(O)(C1CCCCC1)C=1C=CC=CC=1)CCC1=CN=CN=C1 JTVRMZQFJLJITC-AEXFLSAISA-N 0.000 description 1
- REHRHDHVVGECJG-LXNFMVHRSA-N [(1r)-1-methyl-1-(3-pyrimidin-5-ylpropyl)pyrrolidin-1-ium-2-yl]methyl 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C([N@@+]1(C)C(CCC1)COC(=O)C(O)(C1CCCC1)C=1C=CC=CC=1)CCC1=CN=CN=C1 REHRHDHVVGECJG-LXNFMVHRSA-N 0.000 description 1
- NLGSDFICHMQTFC-HNHZEOAVSA-N [(1r)-1-methyl-1-[2-(1,2-oxazol-3-yl)ethyl]piperidin-1-ium-3-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C([N@+]1(C)CC(CCC1)OC(=O)C(O)(C1CCCC1)C=1C=CC=CC=1)CC=1C=CON=1 NLGSDFICHMQTFC-HNHZEOAVSA-N 0.000 description 1
- CTMKTBPDQGLHRR-IQHZPMLTSA-N [(1r)-1-methyl-1-[2-(1,2-oxazol-3-yl)ethyl]piperidin-1-ium-3-yl] 2-hydroxy-2,2-diphenylacetate Chemical compound C([N@+]1(C)CC(CCC1)OC(=O)C(O)(C=1C=CC=CC=1)C=1C=CC=CC=1)CC=1C=CON=1 CTMKTBPDQGLHRR-IQHZPMLTSA-N 0.000 description 1
- MBZIQXAAEBTOIS-MLARANPPSA-N [(1r)-1-methyl-1-[2-(1,2-oxazol-3-yl)ethyl]piperidin-1-ium-3-yl] 9-hydroxyfluorene-9-carboxylate Chemical compound C([N@+]1(C)CC(CCC1)OC(=O)C1(O)C2=CC=CC=C2C2=CC=CC=C21)CC=1C=CON=1 MBZIQXAAEBTOIS-MLARANPPSA-N 0.000 description 1
- BXKABQGBTXKRCE-QREUFCTJSA-O [(1r)-1-methyl-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]piperidin-1-ium-3-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound O1C(C)=CC(NC(=O)C[N@@+]2(C)CC(CCC2)OC(=O)C(O)(C2CCCC2)C=2C=CC=CC=2)=N1 BXKABQGBTXKRCE-QREUFCTJSA-O 0.000 description 1
- BLOGFZOWDQGVSK-SKGNGKIFSA-N [(1r)-1-methyl-1-[3-(1,2-oxazol-3-yl)propyl]piperidin-1-ium-3-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C([N@@+]1(C)CC(CCC1)OC(=O)C(O)(C1CCCCC1)C=1C=CC=CC=1)CCC=1C=CON=1 BLOGFZOWDQGVSK-SKGNGKIFSA-N 0.000 description 1
- NXMNYBIMCMKWOZ-RMBIHJOLSA-N [(1r)-1-methyl-1-[3-(1,2-oxazol-3-yl)propyl]piperidin-1-ium-3-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C([N@@+]1(C)CC(CCC1)OC(=O)C(O)(C1CCCC1)C=1C=CC=CC=1)CCC=1C=CON=1 NXMNYBIMCMKWOZ-RMBIHJOLSA-N 0.000 description 1
- SCIDHRINFMVBON-ITCMONMYSA-N [(1r)-1-methyl-1-[3-(1,2-oxazol-3-yl)propyl]piperidin-1-ium-3-yl] 2-hydroxy-2,2-diphenylacetate Chemical compound C([N@@+]1(C)CC(CCC1)OC(=O)C(O)(C=1C=CC=CC=1)C=1C=CC=CC=1)CCC=1C=CON=1 SCIDHRINFMVBON-ITCMONMYSA-N 0.000 description 1
- LYHWVMZPRUMFLK-QXPUDEPPSA-N [(3R)-3-phenyl-3-pyrrolidin-1-ylbutyl] 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C[C@@](CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O)(C3=CC=CC=C3)N4CCCC4 LYHWVMZPRUMFLK-QXPUDEPPSA-N 0.000 description 1
- VQXBDNOVAJPIIB-UHFFFAOYSA-N [1-methyl-1-(2-pyridin-2-ylethyl)piperidin-1-ium-4-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C1CC(OC(=O)C(O)(C2CCCCC2)C=2C=CC=CC=2)CC[N+]1(C)CCC1=CC=CC=N1 VQXBDNOVAJPIIB-UHFFFAOYSA-N 0.000 description 1
- LRNZHXKANAWMCH-UHFFFAOYSA-N [1-methyl-1-(2-pyridin-4-ylethyl)piperidin-1-ium-4-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C1CC(OC(=O)C(O)(C2CCCCC2)C=2C=CC=CC=2)CC[N+]1(C)CCC1=CC=NC=C1 LRNZHXKANAWMCH-UHFFFAOYSA-N 0.000 description 1
- OEFKCKLOFGDDHJ-UHFFFAOYSA-N [1-methyl-1-(2-pyridin-4-ylethyl)piperidin-1-ium-4-yl] 2-hydroxy-2,2-diphenylacetate Chemical compound C1CC(OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC[N+]1(C)CCC1=CC=NC=C1 OEFKCKLOFGDDHJ-UHFFFAOYSA-N 0.000 description 1
- JVWPGGKJNFUKMO-UHFFFAOYSA-N [1-methyl-1-(2-pyridin-4-ylethyl)piperidin-1-ium-4-yl] 9-hydroxyfluorene-9-carboxylate Chemical compound C1CC(OC(=O)C2(O)C3=CC=CC=C3C3=CC=CC=C32)CC[N+]1(C)CCC1=CC=NC=C1 JVWPGGKJNFUKMO-UHFFFAOYSA-N 0.000 description 1
- ZZLCLLARBWTFOW-UHFFFAOYSA-N [1-methyl-1-(2-pyrimidin-2-ylethyl)piperidin-1-ium-4-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1CC(OC(=O)C(O)(C2CCCC2)C=2C=CC=CC=2)CC[N+]1(C)CCC1=NC=CC=N1 ZZLCLLARBWTFOW-UHFFFAOYSA-N 0.000 description 1
- DVGNAZVJIOBXDG-UHFFFAOYSA-N [1-methyl-1-(2-pyrimidin-2-ylethyl)piperidin-1-ium-4-yl] 9-hydroxyfluorene-9-carboxylate Chemical compound C1CC(OC(=O)C2(O)C3=CC=CC=C3C3=CC=CC=C32)CC[N+]1(C)CCC1=NC=CC=N1 DVGNAZVJIOBXDG-UHFFFAOYSA-N 0.000 description 1
- LRKYPLCQMPMVFV-UHFFFAOYSA-N [1-methyl-1-(2-pyrimidin-4-ylethyl)piperidin-1-ium-4-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C1CC(OC(=O)C(O)(C2CCCCC2)C=2C=CC=CC=2)CC[N+]1(C)CCC1=CC=NC=N1 LRKYPLCQMPMVFV-UHFFFAOYSA-N 0.000 description 1
- OHYIEKWORRDYDQ-UHFFFAOYSA-N [1-methyl-1-(2-pyrimidin-4-ylethyl)piperidin-1-ium-4-yl] 2-hydroxy-2,2-diphenylacetate Chemical compound C1CC(OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC[N+]1(C)CCC1=CC=NC=N1 OHYIEKWORRDYDQ-UHFFFAOYSA-N 0.000 description 1
- IDCVABXQHOSBEF-UHFFFAOYSA-N [1-methyl-1-(2-pyrimidin-4-ylethyl)piperidin-1-ium-4-yl] 9-hydroxyfluorene-9-carboxylate Chemical compound C1CC(OC(=O)C2(O)C3=CC=CC=C3C3=CC=CC=C32)CC[N+]1(C)CCC1=CC=NC=N1 IDCVABXQHOSBEF-UHFFFAOYSA-N 0.000 description 1
- LFAUDCBEBMJTKV-UHFFFAOYSA-N [1-methyl-1-(2-pyrimidin-5-ylethyl)piperidin-1-ium-4-yl] 9-hydroxyfluorene-9-carboxylate Chemical compound C1CC(OC(=O)C2(O)C3=CC=CC=C3C3=CC=CC=C32)CC[N+]1(C)CCC1=CN=CN=C1 LFAUDCBEBMJTKV-UHFFFAOYSA-N 0.000 description 1
- CDIDFEOPOFXBBJ-UHFFFAOYSA-N [1-methyl-1-(3-pyrazin-2-ylpropyl)piperidin-1-ium-4-yl] 9-hydroxyfluorene-9-carboxylate Chemical compound C1CC(OC(=O)C2(O)C3=CC=CC=C3C3=CC=CC=C32)CC[N+]1(C)CCCC1=CN=CC=N1 CDIDFEOPOFXBBJ-UHFFFAOYSA-N 0.000 description 1
- UUGWHHIQQNASLL-UHFFFAOYSA-N [1-methyl-1-(3-pyridin-2-ylpropyl)piperidin-1-ium-4-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C1CC(OC(=O)C(O)(C2CCCCC2)C=2C=CC=CC=2)CC[N+]1(C)CCCC1=CC=CC=N1 UUGWHHIQQNASLL-UHFFFAOYSA-N 0.000 description 1
- RYNDKUMHIHETIE-UHFFFAOYSA-N [1-methyl-1-(3-pyridin-2-ylpropyl)piperidin-1-ium-4-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1CC(OC(=O)C(O)(C2CCCC2)C=2C=CC=CC=2)CC[N+]1(C)CCCC1=CC=CC=N1 RYNDKUMHIHETIE-UHFFFAOYSA-N 0.000 description 1
- XLYFBDLWPYVLNE-UHFFFAOYSA-N [1-methyl-1-(3-pyridin-2-ylpropyl)piperidin-1-ium-4-yl] 9-hydroxyfluorene-9-carboxylate Chemical compound C1CC(OC(=O)C2(O)C3=CC=CC=C3C3=CC=CC=C32)CC[N+]1(C)CCCC1=CC=CC=N1 XLYFBDLWPYVLNE-UHFFFAOYSA-N 0.000 description 1
- DYNXNDPSYPTSPH-UHFFFAOYSA-N [1-methyl-1-(3-pyridin-4-ylpropyl)piperidin-1-ium-4-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C1CC(OC(=O)C(O)(C2CCCCC2)C=2C=CC=CC=2)CC[N+]1(C)CCCC1=CC=NC=C1 DYNXNDPSYPTSPH-UHFFFAOYSA-N 0.000 description 1
- BVRCYOAZGKGEGC-UHFFFAOYSA-N [1-methyl-1-(3-pyrimidin-2-ylpropyl)piperidin-1-ium-4-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1CC(OC(=O)C(O)(C2CCCC2)C=2C=CC=CC=2)CC[N+]1(C)CCCC1=NC=CC=N1 BVRCYOAZGKGEGC-UHFFFAOYSA-N 0.000 description 1
- PRAHQUKWKGLWAZ-UHFFFAOYSA-N [1-methyl-1-(3-pyrimidin-4-ylpropyl)piperidin-1-ium-4-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1CC(OC(=O)C(O)(C2CCCC2)C=2C=CC=CC=2)CC[N+]1(C)CCCC1=CC=NC=N1 PRAHQUKWKGLWAZ-UHFFFAOYSA-N 0.000 description 1
- GBEHJKWDCZGYOA-UHFFFAOYSA-N [1-methyl-1-(3-pyrimidin-5-ylpropyl)piperidin-1-ium-4-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C1CC(OC(=O)C(O)(C2CCCCC2)C=2C=CC=CC=2)CC[N+]1(C)CCCC1=CN=CN=C1 GBEHJKWDCZGYOA-UHFFFAOYSA-N 0.000 description 1
- XUZJYTDDEVDHMK-UHFFFAOYSA-N [1-methyl-1-(3-pyrimidin-5-ylpropyl)piperidin-1-ium-4-yl] 2-hydroxy-2,2-diphenylacetate Chemical compound C1CC(OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC[N+]1(C)CCCC1=CN=CN=C1 XUZJYTDDEVDHMK-UHFFFAOYSA-N 0.000 description 1
- CQBZWEZEJQJTQG-UHFFFAOYSA-N [1-methyl-1-[2-(1,2-oxazol-3-yl)ethyl]piperidin-1-ium-4-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1CC(OC(=O)C(O)(C2CCCC2)C=2C=CC=CC=2)CC[N+]1(C)CCC=1C=CON=1 CQBZWEZEJQJTQG-UHFFFAOYSA-N 0.000 description 1
- MPFOMDKFPIKNDX-UHFFFAOYSA-N [1-methyl-1-[2-(1,2-oxazol-3-yl)ethyl]piperidin-1-ium-4-yl] 9-hydroxyfluorene-9-carboxylate Chemical compound C1CC(OC(=O)C2(O)C3=CC=CC=C3C3=CC=CC=C32)CC[N+]1(C)CCC=1C=CON=1 MPFOMDKFPIKNDX-UHFFFAOYSA-N 0.000 description 1
- CLKRUPRLRZORFY-UHFFFAOYSA-O [1-methyl-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]piperidin-1-ium-4-yl] 2-hydroxy-2,2-diphenylacetate Chemical compound O1C(C)=CC(NC(=O)C[N+]2(C)CCC(CC2)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 CLKRUPRLRZORFY-UHFFFAOYSA-O 0.000 description 1
- XTWOVZYFCZWLRF-UHFFFAOYSA-N [1-methyl-1-[3-(1,2-oxazol-3-yl)propyl]piperidin-1-ium-4-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C1CC(OC(=O)C(O)(C2CCCCC2)C=2C=CC=CC=2)CC[N+]1(C)CCCC=1C=CON=1 XTWOVZYFCZWLRF-UHFFFAOYSA-N 0.000 description 1
- YPFLFUJKZDAXRA-UHFFFAOYSA-N [3-(carbamoylamino)-2-(2,4-dichlorobenzoyl)-1-benzofuran-6-yl] methanesulfonate Chemical compound O1C2=CC(OS(=O)(=O)C)=CC=C2C(NC(N)=O)=C1C(=O)C1=CC=C(Cl)C=C1Cl YPFLFUJKZDAXRA-UHFFFAOYSA-N 0.000 description 1
- IUHFWCGCSVTMPG-UHFFFAOYSA-N [C].[C] Chemical group [C].[C] IUHFWCGCSVTMPG-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 102000015007 alpha-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006816 alpha-adrenergic receptor activity proteins Proteins 0.000 description 1
- PYHXGXCGESYPCW-UHFFFAOYSA-N alpha-phenylbenzeneacetic acid Natural products C=1C=CC=CC=1C(C(=O)O)C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 208000028462 aluminosis Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000010123 anthracosis Diseases 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 206010003441 asbestosis Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
- 239000004044 bronchoconstricting agent Substances 0.000 description 1
- 230000003435 bronchoconstrictive effect Effects 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102220363661 c.36C>A Human genes 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229950010713 carmoterol Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229960004342 cetirizine hydrochloride Drugs 0.000 description 1
- 239000002559 chemokine receptor antagonist Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 201000003139 chronic cystitis Diseases 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 229950001653 cilomilast Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229960002689 clemastine fumarate Drugs 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 229960000354 fexofenadine hydrochloride Drugs 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- GFTXWCQFWLOXAT-UHFFFAOYSA-M magnesium;cyclohexane;bromide Chemical compound [Mg+2].[Br-].C1CC[CH-]CC1 GFTXWCQFWLOXAT-UHFFFAOYSA-M 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- GZUXJHMPEANEGY-UHFFFAOYSA-N methyl bromide Substances BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- DPHDSIQHVGSITN-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 1
- 229960002288 procaterol Drugs 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- XFTQRUTUGRCSGO-UHFFFAOYSA-N pyrazin-2-amine Chemical compound NC1=CN=CC=N1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 208000004003 siderosis Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000003890 substance P antagonist Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0428418.8A GB0428418D0 (en) | 2004-12-24 | 2004-12-24 | Organic compounds |
| PCT/EP2005/013897 WO2006066929A1 (en) | 2004-12-24 | 2005-12-22 | Quaternary ammonium salts as m3 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007007722A true MX2007007722A (es) | 2007-08-14 |
Family
ID=34130968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007007722A MX2007007722A (es) | 2004-12-24 | 2005-12-22 | Sales de amonio cuaternario como antagonistas de m3. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8153669B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1831208B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008525359A (cg-RX-API-DMAC7.html) |
| KR (1) | KR101259654B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101080405B (cg-RX-API-DMAC7.html) |
| AT (1) | ATE521606T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005318424B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0519292A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2589133A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2370832T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB0428418D0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007007722A (cg-RX-API-DMAC7.html) |
| PL (1) | PL1831208T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1831208E (cg-RX-API-DMAC7.html) |
| RU (1) | RU2394031C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006066929A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0428416D0 (en) | 2004-12-24 | 2005-02-02 | Novartis Ag | Organic compounds |
| KR101495708B1 (ko) | 2007-02-23 | 2015-02-25 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | 무스카린 수용체 안타고니스트로 유용한 4차 암모늄 디페닐메틸 화합물 |
| MX2010002576A (es) | 2007-09-07 | 2010-04-01 | Theravance Inc | Compuestos que contienen guanidina, utiles como antagonistas de los receptores muscarinicos. |
| EP2222637A1 (en) | 2007-12-14 | 2010-09-01 | Theravance, Inc. | Amidine-containing compounds useful as muscarinic receptor antagonists |
| DE102008020746A1 (de) | 2008-04-25 | 2009-10-29 | Saltigo Gmbh | Verfahren zur Herstellung von quarternären Salzen von Piperidyl Estern der Mandelsäure |
| EP2935249B1 (en) | 2012-12-19 | 2018-12-12 | Novartis AG | Autotaxin inhibitors |
| JP6223543B2 (ja) | 2013-03-15 | 2017-11-01 | ボドール ラボラトリーズ, インコーポレイテッド | 多汗症の処置のための抗コリン作用性グリコピロレートエステル |
| US20160368873A1 (en) * | 2014-02-17 | 2016-12-22 | Ltt Bio-Pharma Co., Ltd. | Optically Active Form of Mepenzolate, and Ameliorating Agent for Chronic Obstructive Pulmonary Disease Which Contains Same as Active Ingredient |
| US20150259283A1 (en) | 2014-03-13 | 2015-09-17 | Brickell Biotech, Inc. | Formulation for soft anticholinergic analogs |
| EP3134398A1 (en) | 2014-04-24 | 2017-03-01 | Novartis Ag | Autotaxin inhibitors |
| US10472664B2 (en) | 2014-10-03 | 2019-11-12 | Institute For Cancer Research | Screening assay for identification of poly(ADP-ribose) polymerase 1 inhibitors |
| EP3200792A4 (en) | 2014-10-03 | 2018-05-09 | The Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center | Poly (adp-ribose) polymerase 1 inhibitors structurally unrelated to nad |
| HK1253236A1 (zh) | 2015-07-21 | 2019-06-14 | 博多尔实验仪器公司 | 软性抗胆碱能药类似物的制剂 |
| TWI719046B (zh) | 2016-07-21 | 2021-02-21 | 美商波德實驗股份有限公司 | 軟性抗膽鹼類似物之製劑 |
| US11377422B2 (en) | 2019-03-11 | 2022-07-05 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| CA3155568A1 (en) | 2019-11-06 | 2021-05-14 | Bridget Mccarthy Cole | Charged ion channel blockers and methods for use |
| US11332446B2 (en) * | 2020-03-11 | 2022-05-17 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US12162851B2 (en) | 2020-03-11 | 2024-12-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2746966A (en) * | 1953-11-02 | 1956-05-22 | Lakeside Lab Inc | Esters of bis-(nu-substituted-3-hydroxypiperidinium) alkanes |
| GB833820A (en) * | 1957-10-17 | 1960-04-27 | Beecham Res Lab | Improvements in or relating to the preparation of pyrrolidyl esters and quaternary compounds thereof |
| US2956062A (en) * | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| JPS6018661B2 (ja) | 1976-01-01 | 1985-05-11 | 太田製薬株式会社 | 1−(1,3−ジオキソラン−4−イルメチル)ピペリジノ−ル誘導体 |
| JPS5427570A (en) | 1977-07-30 | 1979-03-01 | Ota Pharma | Stereoisomer of 44acyloxyy11 alkyll11*1*33dioxolanee44 ylmethyl* pideridinium salt derivative |
| JPS5679688A (en) | 1979-12-04 | 1981-06-30 | Ota Seiyaku Kk | 4-acyloxy-1- 1,3-dioxoran-2-ylmethyl piperidine derivative and its production |
| JPS5835177A (ja) * | 1981-08-26 | 1983-03-01 | Dainippon Pharmaceut Co Ltd | 2−環状アミノ−2−(1,2−ベンズイソキサゾ−ル−3−イル)酢酸エステル類並びにその酸付加塩類および第4級アンモニウム塩類 |
| JPS58208270A (ja) | 1982-05-28 | 1983-12-03 | Dainippon Pharmaceut Co Ltd | α−環状アミノフエニル酢酸エステル類並びにその酸付加塩類及び第4級アンモニウム塩類 |
| GB9023023D0 (en) | 1990-10-23 | 1990-12-05 | Barlow Richard B | Pharmaceutical compositions |
| SI0937041T1 (en) | 1996-11-11 | 2003-10-31 | Christian R. Noe | Use of a pharmaceutically acceptable salt of (3R,2'R)-3-((Cyclopently-hydroxyphenylacetyl)oxy)-1,1-dimethyl-pyrrolidinium for the preparation of a medicament |
| EP1302458A4 (en) | 2000-07-11 | 2005-10-19 | Banyu Pharma Co Ltd | ESTERDERIVATE |
| ES2206021B1 (es) | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
| WO2004056767A1 (en) * | 2002-12-23 | 2004-07-08 | Ranbaxy Laboratories Limited | 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists |
| PE20050231A1 (es) * | 2003-06-24 | 2005-05-20 | Novartis Ag | Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3 |
| EP1781607A2 (en) * | 2004-08-19 | 2007-05-09 | Ranbaxy Laboratories Limited | Pyrrolidine derivatives as muscarinic receptor antagonists |
-
2004
- 2004-12-24 GB GBGB0428418.8A patent/GB0428418D0/en not_active Ceased
-
2005
- 2005-12-22 KR KR1020077014261A patent/KR101259654B1/ko not_active Expired - Fee Related
- 2005-12-22 PT PT05820639T patent/PT1831208E/pt unknown
- 2005-12-22 RU RU2007128085/04A patent/RU2394031C2/ru not_active IP Right Cessation
- 2005-12-22 WO PCT/EP2005/013897 patent/WO2006066929A1/en not_active Ceased
- 2005-12-22 CA CA002589133A patent/CA2589133A1/en not_active Abandoned
- 2005-12-22 JP JP2007547368A patent/JP2008525359A/ja active Pending
- 2005-12-22 ES ES05820639T patent/ES2370832T3/es not_active Expired - Lifetime
- 2005-12-22 US US11/721,989 patent/US8153669B2/en not_active Expired - Fee Related
- 2005-12-22 AU AU2005318424A patent/AU2005318424B2/en not_active Ceased
- 2005-12-22 MX MX2007007722A patent/MX2007007722A/es active IP Right Grant
- 2005-12-22 AT AT05820639T patent/ATE521606T1/de active
- 2005-12-22 EP EP05820639A patent/EP1831208B1/en not_active Expired - Lifetime
- 2005-12-22 BR BRPI0519292-7A patent/BRPI0519292A2/pt not_active IP Right Cessation
- 2005-12-22 PL PL05820639T patent/PL1831208T3/pl unknown
- 2005-12-22 CN CN2005800429764A patent/CN101080405B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8153669B2 (en) | 2012-04-10 |
| PL1831208T3 (pl) | 2012-01-31 |
| BRPI0519292A2 (pt) | 2009-01-06 |
| EP1831208B1 (en) | 2011-08-24 |
| RU2007128085A (ru) | 2009-01-27 |
| JP2008525359A (ja) | 2008-07-17 |
| EP1831208A1 (en) | 2007-09-12 |
| AU2005318424A1 (en) | 2006-06-29 |
| AU2005318424B2 (en) | 2009-10-08 |
| KR20070089953A (ko) | 2007-09-04 |
| ES2370832T3 (es) | 2011-12-23 |
| CN101080405B (zh) | 2011-05-11 |
| PT1831208E (pt) | 2011-10-31 |
| GB0428418D0 (en) | 2005-02-02 |
| HK1109767A1 (en) | 2008-06-20 |
| ATE521606T1 (de) | 2011-09-15 |
| CN101080405A (zh) | 2007-11-28 |
| US20090227590A1 (en) | 2009-09-10 |
| CA2589133A1 (en) | 2006-06-29 |
| KR101259654B1 (ko) | 2013-04-30 |
| WO2006066929A1 (en) | 2006-06-29 |
| RU2394031C2 (ru) | 2010-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1811999B1 (en) | Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists | |
| US8153669B2 (en) | Quaternary ammonium salts as M3 antagonists | |
| US7947730B2 (en) | Piperidinium and pyrrolidinium derivatives as ligands for the muscarinic M3 receptor | |
| EP1831202B1 (en) | Pyrrolinidium derivatives as m3 muscarinic receptors | |
| HK1109767B (en) | Quaternary ammonium salts as m3 antagonists | |
| HK1087704A1 (en) | Quinuclidine derivatives binding to mucarinic m3 receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |